109 related articles for article (PubMed ID: 32073312)
1. Discriminations of active from inactive HDAC8 inhibitors Part II: Bayesian classification study to find molecular fingerprints.
Amin SA; Banerjee S; Adhikari N; Jha T
SAR QSAR Environ Res; 2020 Apr; 31(4):245-260. PubMed ID: 32073312
[TBL] [Abstract][Full Text] [Related]
2. Diverse classes of HDAC8 inhibitors: in search of molecular fingerprints that regulate activity.
Amin SA; Adhikari N; Jha T
Future Med Chem; 2018 Jul; 10(13):1589-1602. PubMed ID: 29953251
[TBL] [Abstract][Full Text] [Related]
3. Development of decision trees to discriminate HDAC8 inhibitors and non-inhibitors using recursive partitioning.
Amin SA; Adhikari N; Jha T
J Biomol Struct Dyn; 2021 Jan; 39(1):1-8. PubMed ID: 31530244
[TBL] [Abstract][Full Text] [Related]
4. Essential elements regulating HDAC8 inhibition: a classification based structural analysis and enzyme-inhibitor interaction study of hydroxamate based HDAC8 inhibitors.
Banerjee S; Amin SA; Adhikari N; Jha T
J Biomol Struct Dyn; 2020 Nov; 38(18):5513-5525. PubMed ID: 31830865
[TBL] [Abstract][Full Text] [Related]
5. A comparative quantitative structural assessment of benzothiazine-derived HDAC8 inhibitors by predictive ligand-based drug designing approaches.
Banerjee S; Baidya SK; Adhikari N; Jha T
SAR QSAR Environ Res; 2022 Dec; 33(12):987-1011. PubMed ID: 36533308
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.
Banerjee S; Adhikari N; Amin SA; Jha T
Eur J Med Chem; 2019 Feb; 164():214-240. PubMed ID: 30594678
[TBL] [Abstract][Full Text] [Related]
7. A lazy learning-based QSAR classification study for screening potential histone deacetylase 8 (HDAC8) inhibitors.
Cao GP; Arooj M; Thangapandian S; Park C; Arulalapperumal V; Kim Y; Kwon YJ; Kim HH; Suh JK; Lee KW
SAR QSAR Environ Res; 2015; 26(5):397-420. PubMed ID: 25986171
[TBL] [Abstract][Full Text] [Related]
8. QSAR modeling to design selective histone deacetylase 8 (HDAC8) inhibitors.
Cao GP; Thangapandian S; Son M; Kumar R; Choi YJ; Kim Y; Kwon YJ; Kim HH; Suh JK; Lee KW
Arch Pharm Res; 2016 Oct; 39(10):1356-1369. PubMed ID: 27542119
[TBL] [Abstract][Full Text] [Related]
9. Docking and QSAR Studies of Aryl-valproic Acid Derivatives to Identify Antiproliferative Agents Targeting the HDAC8.
Martínez-Pacheco H; Ramírez-Galicia G; Vergara-Arias M; Gertsch J; Fragoso-Vazquez JM; Mendez-Luna D; Abujamra AL; Cristina CL; Cecilia RM; Mendoza-Lujambio I; Correa-Basurto J
Anticancer Agents Med Chem; 2017; 17(7):927-940. PubMed ID: 27774878
[TBL] [Abstract][Full Text] [Related]
10. Structural exploration of tetrahydroisoquinoline derivatives as HDAC8 inhibitors through multi-QSAR modeling study.
Banerjee S; Adhikari N; Amin SA; Jha T
J Biomol Struct Dyn; 2020 Mar; 38(5):1551-1564. PubMed ID: 31074329
[TBL] [Abstract][Full Text] [Related]
11. Designing potential HDAC3 inhibitors to improve memory and learning.
Amin SA; Adhikari N; Jha T; Ghosh B
J Biomol Struct Dyn; 2019 May; 37(8):2133-2142. PubMed ID: 30044204
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity.
Trivedi P; Adhikari N; Amin SA; Bobde Y; Ganesh R; Jha T; Ghosh B
Eur J Pharm Sci; 2019 Oct; 138():105046. PubMed ID: 31421254
[TBL] [Abstract][Full Text] [Related]
13. Influence of oil contamination on in vitro bond strength of bonding agents to dental substrates.
Matos AB; Oliveira DC; Vieira SN; Netto NG; Powers JM
Am J Dent; 2008 Apr; 21(2):101-4. PubMed ID: 18578177
[TBL] [Abstract][Full Text] [Related]
14. Selective and nonselective HDAC8 inhibitors: a therapeutic patent review.
Adhikari N; Amin SA; Jha T
Pharm Pat Anal; 2018 Nov; 7(6):259-276. PubMed ID: 30632447
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
[TBL] [Abstract][Full Text] [Related]
16. Ligand release mechanisms and channels in histone deacetylases.
Kalyaanamoorthy S; Chen YP
J Comput Chem; 2013 Oct; 34(26):2270-83. PubMed ID: 23893931
[TBL] [Abstract][Full Text] [Related]
17. Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8.
Stoddard SV; May XA; Rivas F; Dodson K; Vijayan S; Adhika S; Parker K; Watkins DL
Mol Inform; 2019 Mar; 38(3):e1800080. PubMed ID: 30369061
[TBL] [Abstract][Full Text] [Related]
18. Covalent inhibition of histone deacetylase 8 by 3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine.
Muth M; Jänsch N; Kopranovic A; Krämer A; Wössner N; Jung M; Kirschhöfer F; Brenner-Weiß G; Meyer-Almes FJ
Biochim Biophys Acta Gen Subj; 2019 Mar; 1863(3):577-585. PubMed ID: 30611847
[TBL] [Abstract][Full Text] [Related]
19. Identification of structural fingerprints for ABCG2 inhibition by using Monte Carlo optimization, Bayesian classification, and structural and physicochemical interpretation (SPCI) analysis.
Ghosh K; Bhardwaj B; Amin SA; Jha T; Gayen S
SAR QSAR Environ Res; 2020 Jun; 31(6):439-455. PubMed ID: 32539470
[TBL] [Abstract][Full Text] [Related]
20. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
